Literature DB >> 15742121

Relationship between clinical factors and neuropsychiatric manifestations in systemic lupus erythematosus.

Yasuhiro Shimojima1, Masayuki Matsuda, Takahisa Gono, Wataru Ishii, Shu-ichi Ikeda.   

Abstract

Neuropsychiatric symptoms are often seen in patients with systemic lupus erythematosus (SLE). To investigate the relationship between involvement of the nervous system and clinical factors, including autoantibodies and the activity of SLE, we retrospectively reviewed 25 patients with neuropsychiatric SLE (NPSLE, mean age: 35.2+/-12.2 years). As controls 37 SLE patients without neuropsychiatric manifestations (mean age: 31.8+/-15.8 years) were employed in this study. At the onset no significant differences were seen in any clinical factors between the patients and the controls except for serum antinuclear antibodies. In relapse, the patients with NPSLE showed significantly lower levels of Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores without neuropsychiatric evaluation (p<0.0001), erythrocyte sedimentation rate (ESR, p<0.005), and antinuclear and anti-double-stranded DNA antibodies (p<0.005) and higher WBC values (p<0.05) than at the onset. Also in the patients with relapsing NPSLE similar significant differences were seen in these parameters between onset and relapse (p<0.005). Despite a lack of significant differences, the cerebrospinal fluid showed lower values in cell counts, total protein, and IgG in relapse than at onset. These results suggest that there are no clinical factors that predict the development of NPSLE and that relapse can occur with low disease activity in the nervous system even with an inactive state of other organ involvement. Since NPSLE may suddenly relapse with a slight change in common disease activation markers, including inflammatory reactions, autoantibodies, and complements in serum and CSF findings, adequate corticosteroid and/or immunosuppressive agents should be given at the onset and gradually be tapered after recovery, while looking out for recurrence.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15742121     DOI: 10.1007/s10067-004-1060-y

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  34 in total

1.  Predictors of clinical outcome and radiologic progression in patients with neuropsychiatric manifestations of systemic lupus erythematosus.

Authors:  F B Karassa; J P Ioannidis; K A Boki; G Touloumi; M I Argyropoulou; K A Strigaris; H M Moutsopoulos
Journal:  Am J Med       Date:  2000-12-01       Impact factor: 4.965

2.  Cognitive impairment in patients with systemic lupus erythematosus.

Authors:  J G Hanly; J D Fisk; G Sherwood; E Jones; J V Jones; B Eastwood
Journal:  J Rheumatol       Date:  1992-04       Impact factor: 4.666

3.  Antiribosomal P0 protein antibodies react with the surface of human umbilical vein endothelial cells.

Authors:  T Yoshio; J Masuyama; S Kano
Journal:  J Rheumatol       Date:  1996-07       Impact factor: 4.666

4.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

5.  Association of anti-Sm antibodies with organic brain syndrome secondary to systemic lupus erythematosus.

Authors:  S Hirohata; M Kosaka
Journal:  Lancet       Date:  1994-03-26       Impact factor: 79.321

Review 6.  Antinuclear antibody profiles in relation to specific disease manifestations of systemic lupus erythematosus.

Authors:  A J Swaak; V Huysen; J C Nossent; R J Smeenk
Journal:  Clin Rheumatol       Date:  1990-03       Impact factor: 2.980

Review 7.  The central nervous system in systemic lupus erythematosus. Part 2. Pathogenetic mechanisms of clinical syndromes: a literature investigation.

Authors:  F G I Jennekens; L Kater
Journal:  Rheumatology (Oxford)       Date:  2002-06       Impact factor: 7.580

8.  Cerebrospinal fluid IgM, IgA, and IgG indexes in systemic lupus erythematosus. Their use as estimates of central nervous system disease activity.

Authors:  S Hirohata; S Hirose; T Miyamoto
Journal:  Arch Intern Med       Date:  1985-10

9.  Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement.

Authors:  S Hirohata; T Miyamoto
Journal:  Arthritis Rheum       Date:  1990-05

10.  Increased lymphocyte death by neglect-apoptosis is associated with lymphopenia and autoantibodies in lupus patients presenting with neuropsychiatric manifestations.

Authors:  Lucienir M Silva; Aglair B Garcia; Eduardo A Donadi
Journal:  J Neurol       Date:  2002-08       Impact factor: 4.849

View more
  8 in total

1.  Predictors for neuropsychiatric development in Chinese adolescents with systemic lupus erythematosus.

Authors:  Jing Dong; Hua Li; Ji-bo Wang; Yuan Yao; Qing-rui Yang
Journal:  Rheumatol Int       Date:  2011-07-26       Impact factor: 2.631

Review 2.  Diagnosis and management of neuropsychiatric SLE.

Authors:  John G Hanly
Journal:  Nat Rev Rheumatol       Date:  2014-02-11       Impact factor: 20.543

3.  Discriminating infectious meningitis versus neuropsychiatric involvement in patients with systemic lupus erythematosus: a single-center experience.

Authors:  Jinyun Chen; Xuebing Feng; Hong Wang; Bingzhu Hua; Congzhu Ding; Bujun Liu; Lingyun Sun
Journal:  Clin Rheumatol       Date:  2014-06-20       Impact factor: 2.980

Review 4.  The MRL/lpr mouse strain as a model for neuropsychiatric systemic lupus erythematosus.

Authors:  Maria Gulinello; Chaim Putterman
Journal:  J Biomed Biotechnol       Date:  2011-02-10

5.  Blood-based candidate biomarkers of the presence of neuropsychiatric systemic lupus erythematosus in children.

Authors:  Hermine I Brunner; Marisa S Klein-Gitelman; Frank Zelko; Dean W Beebe; Dirk Foell; Jiha Lee; Ahmad Zaal; Jordan Jones; Tresa Roebuck-Spencer; Jun Ying
Journal:  Lupus Sci Med       Date:  2014-11-05

6.  Differences between central nervous system infection and neuropsychiatric systemic lupus erythematosus in patients with systemic lupus erythematosus.

Authors:  Hongli Fang; Likang Lan; Yanzhou Qu; Qiankun Zhang; Jin Lv
Journal:  J Int Med Res       Date:  2017-08-21       Impact factor: 1.671

Review 7.  Molecular Biomarkers in Multiple Sclerosis and Its Related Disorders: A Critical Review.

Authors:  Maryam Gul; Amirhossein Azari Jafari; Muffaqam Shah; Seyyedmohammadsadeq Mirmoeeni; Safee Ullah Haider; Sadia Moinuddin; Ammar Chaudhry
Journal:  Int J Mol Sci       Date:  2020-08-21       Impact factor: 5.923

8.  Selective Impairment of Spatial Cognition Caused by Autoantibodies to the N-Methyl-D-Aspartate Receptor.

Authors:  Eric H Chang; Bruce T Volpe; Meggan Mackay; Cynthia Aranow; Philip Watson; Czeslawa Kowal; Justin Storbeck; Paul Mattis; RoseAnn Berlin; Huiyi Chen; Simone Mader; Tomás S Huerta; Patricio T Huerta; Betty Diamond
Journal:  EBioMedicine       Date:  2015-05-30       Impact factor: 8.143

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.